Novo Nordisk

Novo Nordisk A/S is a global leader in the pharmaceutical and healthcare sectors, founded in 1923 by August Krogh, H.C. Hagedorn, and August Kongsted in Denmark. With a strong heritage in diabetes care, the company has expanded its footprint to become one of the largest pharmaceutical companies worldwide, specializing in innovative treatments for chronic diseases. Headquartered in Bagsværd, Denmark, Novo Nordisk operates with over 78,000 employees, driving scientific breakthroughs and expanding access to essential medicines.

Known primarily for its diabetes care medications and devices, obesity treatments, and therapies in hemostasis management, growth hormone, and hormone replacement, Novo Nordisk serves customers in 168 countries with affiliates in 80 countries. The company’s commitment to sustainability and corporate social responsibility further sets it apart in the pharmaceutical industry.

When Was Novo Nordisk Established?

Founded: 1923
Founders: August Krogh, H.C. Hagedorn, August Kongsted
Headquarters: Bagsværd, Denmark
Industry: Pharmaceuticals, Healthcare
Employees: 78,400 globally
Annual Revenue: 290.4 billion DKK (2024)
Operating Countries: Products sold in 168 countries; affiliates in 80 countries

Novo Nordisk Mission Statement

“To drive change to defeat serious chronic diseases, built upon our heritage in diabetes.”

What Is Novo Nordisk Known For?

Novo Nordisk is recognized for its pioneering contributions to diabetes care and innovative treatments that improve patient outcomes worldwide.

Leading Diabetes Care Products

The company’s portfolio includes groundbreaking diabetes treatments such as Ozempic (semaglutide), Victoza (liraglutide), Levemir (insulin detemir), Tresiba (insulin degludec), and NovoLog (insulin aspart). These products offer effective blood sugar control and improved quality of life for millions living with diabetes.

Innovative Obesity Treatments

Wegovy (semaglutide) is a notable obesity treatment from Novo Nordisk, addressing a critical global health challenge and supporting sustainable weight management as part of comprehensive care.

Comprehensive Pharmaceutical Solutions

Beyond diabetes and obesity care, Novo Nordisk develops therapies for hemostasis management with NovoSeven, growth hormone therapy with Norditropin, and hormone replacement treatments, showcasing a broad impact across several chronic conditions.

In Which Countries Does Novo Nordisk Operate?

Novo Nordisk's products are available in 168 countries, supported by affiliates in 80 countries worldwide. The company also maintains production facilities strategically located in Belgium, Brazil, China, Denmark, France, Italy, and the United States, enabling efficient global distribution and supply chain management.

With a significant presence in the United States, which includes production and research operations, Novo Nordisk serves a vital healthcare market while reinforcing its commitment to meeting diverse international needs.

Who Owns Novo Nordisk?

Novo Nordisk is a publicly traded company listed on the Copenhagen Stock Exchange, owned by institutional and private investors. It remains committed to transparency, ethical business practices, and sustainable growth as part of its corporate governance.

Is Novo Nordisk Currently Hiring?

You can check out the open positions that Novo Nordisk has right here on OysterLink.